Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

Rhea-AI Summary

Precision BioSciences (NASDAQ: DTIL) will release its Q2 2022 financial results and provide a business update on August 8, 2022. The company is focused on advancing its proprietary ARCUS® genome editing platform, which targets both ex vivo CAR T immunotherapies and in vivo gene editing therapies. Precision BioSciences aims to address genetic and infectious diseases lacking adequate treatments, showcasing its commitment to therapeutic safety and delivery.

Positive

• Development of the ARCUS® genome editing platform focused on therapeutic safety and control.
• Pipeline includes multiple ‘off-the-shelf’ CAR T immunotherapy candidates.

Negative

• None.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005096/en/

Investor Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences release its Q2 2022 financial results?

Precision BioSciences will publish its Q2 2022 financial results on August 8, 2022.

What is the main focus of Precision BioSciences?

Precision BioSciences is focused on developing ARCUS®-based gene editing therapies for genetic and infectious diseases.

What stock symbol is associated with Precision BioSciences?

The stock symbol for Precision BioSciences is DTIL.